TY - JOUR
T1 - Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels
AU - Reddy, Krishna
AU - Zhou, Zhichao
AU - Schadler, Keri
AU - Jia, Shu Fang
AU - Kleinerman, Eugenie S.
PY - 2008/6/1
Y1 - 2008/6/1
N2 - Hematopoietic progenitor cells arising from bone marrow (BM) are known to contribute to the formation and expansion of tumor vasculature. However, whether different subsets of these cells have different roles in this process is unclear. To investigate the roles of BM-derived progenitor cell subpopulations in the formation of tumor vasculature in a Ewing's sarcoma model, we used a functional assay based on endothelial cell and pericyte differentiation in vivo. Fluorescence-activated cell sorting of human cord blood/BM or mouse BM from green fluorescent protein transgenic mice was used to isolate human CD34 +/CD38-, CD34+/CD45+, and CD34 -/CD45+ cells and mouse Sca1+/Gr1+, Sca1-/Gr1+, VEGFR1+, and VEGFR2+ cells. Each of these progenitor subpopulations was separately injected intravenously into nude mice bearing Ewing's sarcoma tumors. Tumors were resected 1 week later and analyzed using immunohistochemistry and confocal microscopy for the presence of migrated progenitor cells expressing endothelial,pericyte,or inflammatory cell surface markers. We showed two distinct patterns of stem cell infiltration. Human CD34+/CD45 + and CD34+/CD38- and murine VEGFR2+ and Sca1+/Gr1+ cells migrated to Ewing's tumors, colocalized with the tumor vascular network, and differentiated into cells expressing either endothelial markers (mouse CD31 or human vascular endothelial cadherin) or the pericyte markers desmin and α-smooth muscle actin. By contrast,human CD34-/CD45+ and mouse Sca1 -/Gr1+ cells migrated predominantly to sites outside of the tumor vasculature and differentiated into monocytes/macrophages expressing F4/80 or CD14. Our data indicate that only specific BM stem/progenitor subpopulations participate in Ewing's sarcoma tumor vasculogenesis.
AB - Hematopoietic progenitor cells arising from bone marrow (BM) are known to contribute to the formation and expansion of tumor vasculature. However, whether different subsets of these cells have different roles in this process is unclear. To investigate the roles of BM-derived progenitor cell subpopulations in the formation of tumor vasculature in a Ewing's sarcoma model, we used a functional assay based on endothelial cell and pericyte differentiation in vivo. Fluorescence-activated cell sorting of human cord blood/BM or mouse BM from green fluorescent protein transgenic mice was used to isolate human CD34 +/CD38-, CD34+/CD45+, and CD34 -/CD45+ cells and mouse Sca1+/Gr1+, Sca1-/Gr1+, VEGFR1+, and VEGFR2+ cells. Each of these progenitor subpopulations was separately injected intravenously into nude mice bearing Ewing's sarcoma tumors. Tumors were resected 1 week later and analyzed using immunohistochemistry and confocal microscopy for the presence of migrated progenitor cells expressing endothelial,pericyte,or inflammatory cell surface markers. We showed two distinct patterns of stem cell infiltration. Human CD34+/CD45 + and CD34+/CD38- and murine VEGFR2+ and Sca1+/Gr1+ cells migrated to Ewing's tumors, colocalized with the tumor vascular network, and differentiated into cells expressing either endothelial markers (mouse CD31 or human vascular endothelial cadherin) or the pericyte markers desmin and α-smooth muscle actin. By contrast,human CD34-/CD45+ and mouse Sca1 -/Gr1+ cells migrated predominantly to sites outside of the tumor vasculature and differentiated into monocytes/macrophages expressing F4/80 or CD14. Our data indicate that only specific BM stem/progenitor subpopulations participate in Ewing's sarcoma tumor vasculogenesis.
UR - http://www.scopus.com/inward/record.url?scp=50349093567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=50349093567&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-07-2189
DO - 10.1158/1541-7786.MCR-07-2189
M3 - Article
C2 - 18567797
AN - SCOPUS:50349093567
SN - 1541-7786
VL - 6
SP - 929
EP - 936
JO - Molecular Cancer Research
JF - Molecular Cancer Research
IS - 6
ER -